Dr. Evan M Graboyes, M.D.
Claim this profileMedical University of South Carolina
Studies Squamous Cell Carcinoma
Studies Head and Neck Cancers
5 reported clinical trials
11 drugs studied
Area of expertise
1Squamous Cell Carcinoma
p16 positive
Stage IV
Stage III
2Head And Neck Cancers
Stage IV
Stage III
p16 positive
Affiliated Hospitals
Clinical Trials Evan M Graboyes, M.D. is currently running
Navigation Intervention
for Head and Neck Cancers
The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial aims to answer are: * Does ENDURE improve initiation of timely PORT relative to treatment as usual? * Does ENDURE improve initiation of timely PORT in regards to racial disparities relative to treatment as usual? * What are the mechanisms through which ENDURE improves timeliness to treatment?
Recruiting1 award N/A7 criteria
HN-STAR
for Head and Neck Cancer
People who have been treated for head and neck cancer (HNC survivors) can experience serious consequences from their cancer and its treatment, ongoing risks of new cancers, and other unrelated illnesses. These concerns pose challenges to the provision of comprehensive care to HNC survivors. We created HN-STAR to facilitate and tailor the ongoing care of HNC survivors. Survivors use HN-STAR on a computer or tablet to answer questions about symptoms and health concerns before a routine visit with a cancer care provider. During the clinic visit, the provider uses HN-STAR to see evidence-based recommendations for managing each concern reported by the survivor. The provider and survivor discuss recommendations and select appropriate actions (e.g., testing, referrals, prescriptions, self-management). HN-STAR produces a survivorship care plan that includes all reported concerns and the actions selected in clinic. The survivorship care plan is given to the survivor and the primary care provider. Three months, six months, and nine months later, the survivor uses HN-STAR from home (or clinic) to report their concerns again, and a new survivorship care plan is created each time. Our trial randomizes 20-36 oncology practices from the National Community Oncology Research Program to use HN-STAR or provide usual care to 298-400 recent survivors of head and neck cancer. We hypothesize that survivors in the HN-STAR arm will have greater improvement in patient-centered outcomes (including cancer-related well-being, symptoms, and patient activation) over one year compared to survivors in the usual care arm, measured by surveys at baseline and one year later. We also hypothesize that survivors in the HN-STAR arm will be more likely to receive care that is aligned with evidence-based recommendations during the year of the study than survivors in the usual care arm. Our final aim investigates the implementation of HN-STAR in clinical practice, using interviews and surveys of survivors, providers, and other clinic staff to understand the feasibility, acceptability, appropriateness, and other aspects of providing survivorship care to head and neck cancer survivors.
Recruiting1 award N/A7 criteria
More about Evan M Graboyes, M.D.
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Evan M Graboyes, M.D. has experience with
- ENDURE
- NDURE
- Attention Control
- BRIGHT
- HN-STAR Intervention
- Computed Tomography (CT)
Breakdown of trials Evan M Graboyes, M.D. has run
Squamous Cell Carcinoma
Head and Neck Cancers
Oral Cancers
Mouth cancer
Pharyngeal and Laryngeal Neoplasms
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Evan M Graboyes, M.D. specialize in?
Evan M Graboyes, M.D. focuses on Squamous Cell Carcinoma and Head and Neck Cancers. In particular, much of their work with Squamous Cell Carcinoma has involved p16 positive patients, or patients who are Stage IV.
Is Evan M Graboyes, M.D. currently recruiting for clinical trials?
Yes, Evan M Graboyes, M.D. is currently recruiting for 3 clinical trials in Charleston South Carolina. If you're interested in participating, you should apply.
Are there any treatments that Evan M Graboyes, M.D. has studied deeply?
Yes, Evan M Graboyes, M.D. has studied treatments such as ENDURE, NDURE, Attention Control.
What is the best way to schedule an appointment with Evan M Graboyes, M.D.?
Apply for one of the trials that Evan M Graboyes, M.D. is conducting.
What is the office address of Evan M Graboyes, M.D.?
The office of Evan M Graboyes, M.D. is located at: Medical University of South Carolina, Charleston, South Carolina 29425 United States. This is the address for their practice at the Medical University of South Carolina.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.